A Phase 1/2 interventional study of mRNA-1975 and mRNA-1982 in Lyme Disease, sponsored by ModernaTX, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Lyme Disease with a site in United States — 15 open to participants now, 17 under way, 2 of them phase 3. Lyme Disease · United States.
Among the 54 studies in Lyme Disease with a site in United States, this one is the 5th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2023, is one of 4 in phase 1/2, and was the 44th registered.
98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.
Browse Lyme Disease studies →15 of the 54 studies in Lyme Disease with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 7+ · Healthy volunteers
Columbia University · Sites in United States
Ages 18–70
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Children's National Research Institute · Sites in United States
Ages 18+ · Women only
Children's National Research Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 10
First in 1996; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 807 is above the median of 120 across 52 interventional studies indexed under Lyme Disease.
Median enrollment 72 across the 33 interventional studies, 410 across the 21 observational. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Moderna, Inc. has 2 studies filed under Lyme Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Lyme Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07500506Phase 3PfizerA Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine | 2026-12-04 |
| NCT05776251Columbia UniversitytaVNS for Persistent Symptoms From Lyme Disease | 2026-11 |
| NCT06026969Children's National Research InstitutePregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure | 2026-12 |
| NCT06511050Icahn School of Medicine at Mount SinaiLumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | 2026-12 |
| NCT06397794Children's National Research InstituteNavigating Pregnancy and Parenthood With Lyme Disease | 2026-12-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 54 studies in Lyme Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 3 intramuscular (IM) injections of the mRNA-1975 vaccine at Dose Level 1 on Days 1, 57, and 169.
Biological: mRNA-1975
Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose level 2 on Days 1, 57, and 169.
Biological: mRNA-1975
Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose Level 3 on Days 1, 57, and 169.
Biological: mRNA-1975
Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose level 4 on Days 1, 57, and 169.
Biological: mRNA-1975
Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose Level 1 on Days 1, 57, and 169.
Biological: mRNA-1982
Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose Level 2 on Days 1, 57, and 169.
Biological: mRNA-1982
Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose level 3 on Days 1, 57, and 169.
Biological: mRNA-1982
Participants will receive 3 IM injections of vaccine-matching placebo on Days 1, 57, and 169.
Biological: Placebo
Dispersion delivered IM
Also known as: SR1-7
Dispersion delivered IM
Also known as: SR1
Solution delivered IM
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection
Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Up to 7 days after Day 1 injection
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 57 Injection
Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Up to 7 days after Day 57 injection
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 169 Injection
Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Up to 7 days after Day 169 injection
Number of Participants With Unsolicited AEs
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Up to 28 days post any injection
Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), SAEs, and AEs Leading to Study Discontinuation
A MAAE is an AE that led to an unscheduled visit to a healthcare practitioner. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor were required. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Day 1 up to Month 18
Geometric Mean Concentration (GMC) of Anti-Outer Surface Protein (Anti-OspA) Binding Immunoglobulin (IgG) Antibodies for Serotype (SR-1) Antigen Measured by Enzyme-Linked Immunosorbent Assay (ELISA)
Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values reported greater than upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 41.4 nanograms (ng)/milliliter (mL) and ULOQ was 428000 ng/mL for manual assay; LLOQ was 47.6 ng/mL and 583000 ng/mL for automated assay for SR-1 IgG antibody. 95% confidence interval (CI) for GM value was calculated based on the t-distribution of the log-transformed values , then back transformed to the original scale for presentation.
Time frame: Days 1, 29, 85 and 197
GMC of Anti-OspA Binding IgG Antibodies for SR-2 Antigen Measured by ELISA
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 30 ng/mL and ULOQ was 214000 ng/mL for manual assay; LLOQ was 66.6 ng/mL and 215000 ng/mL for automated assay for SR-2 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
Time frame: Days 1, 29, 85, and 197
GMC of Anti-OspA Binding IgG Antibodies for SR-3 Antigen Measured by ELISA
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 14.5 ng/mL and ULOQ was 299000 ng/mL for manual assay; LLOQ was 62.5 ng/mL and 296000 ng/mL for automated assay for SR-3 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
Time frame: Days 1, 29, 85 and 197
GMC of Anti-OspA Binding IgG Antibodies for SR-4 Antigen Measured by ELISA
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 32.6 ng/mL and ULOQ was 292000 ng/mL for manual assay; LLOQ was 59.7 ng/mL and 264000 ng/mL for automated assay for SR-4 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
Time frame: Days 1, 29, 85 and 197
GMC of Anti-OspA Binding IgG Antibodies for SR-5 Antigen Measured by ELISA
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 45.5 ng/mL and ULOQ was 298000 ng/mL for manual assay; LLOQ was 84.2 ng/mL and 319000 ng/mL for automated assay for SR-5 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
Time frame: Days 1, 29, 85 and 197
GMC of Anti-OspA Binding IgG Antibodies for SR-6 Antigen Measured by ELISA
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 18.1 ng/mL and ULOQ was 203000 ng/mL for manual assay; LLOQ was 68.7 ng/mL and 248000 ng/mL for automated assay for SR-6 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
Time frame: Days 1, 29, 85 and 197
GMC of Anti-OspA Binding IgG Antibodies for SR-7 Antigen Measured by ELISA
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 13 ng/mL and ULOQ was 197000 ng/mL for manual assay; LLOQ was 78.9 ng/mL and 174000 ng/mL for automated assay for SR-7 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
Time frame: Days 1, 29, 85 and 197
Geometric Mean Fold Rise (GMFR) of Anti-OspA Binding IgG Antibody Concentration for SR-1 Antigen
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 41.4 ng/mL and ULOQ was 428000 ng/mL for manual assay; LLOQ was 47.6 ng/mL and 583000 ng/mL for automated assay for SR-1 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation.
Time frame: Days 29, 85 and 197
GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-2 Antigen
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 30 ng/mL and ULOQ was 214000 ng/mL for manual assay; LLOQ was 66.6 ng/mL and 215000 ng/mL for automated assay for SR-2 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
Time frame: Days 29, 85 and 197
GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-3 Antigen
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 14.5 ng/mL and ULOQ was 299000 ng/mL for manual assay; LLOQ was 62.5 ng/mL and 296000 ng/mL for automated assay for SR-3 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
Time frame: Days 29, 85 and 197
GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-4 Antigen
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 32.6 ng/mL and ULOQ was 292000 ng/mL for manual assay; LLOQ was 59.7 ng/mL and 264000 ng/mL for automated assay for SR-4 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
Time frame: Days 29, 85 and 197
GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-5 Antigen
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 45.5 ng/mL and ULOQ was 298000 ng/mL for manual assay; LLOQ was 84.2 ng/mL and 319000 ng/mL for automated assay for SR-5 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
Time frame: Days 29, 85 and 197
GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-6 Antigen
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 18.1 ng/mL and ULOQ was 203000 ng/mL for manual assay; LLOQ was 68.7 ng/mL and 248000 ng/mL for automated assay for SR-6 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
Time frame: Days 29, 85 and 197
GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-7 Antigen
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 13 ng/mL and ULOQ was 197000 ng/mL for manual assay; LLOQ was 78.9 ng/mL and 174000 ng/mL for automated assay for SR-7 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
Time frame: Days 29, 85 and 197
Number of Deaths Related to Study Drug
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.
Time frame: Day 1 up to Month 18
| Milestone | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo |
|---|---|---|---|---|---|---|---|---|
| Started | 100 | 101 | 99 | 102 | 99 | 100 | 104 | 102 |
| Received first injection | 100 | 101 | 99 | 102 | 99 | 100 | 104 | 101 |
| Received second injection | 97 | 98 | 97 | 99 | 94 | 97 | 99 | 96 |
| Received third injection | 93 | 95 | 90 | 94 | 93 | 93 | 92 | 95 |
| Full analysis set | 100 | 101 | 99 | 102 | 99 | 100 | 104 | 101 |
| Safety analysis set | 100 | 101 | 99 | 102 | 98 | 100 | 105 | 101 |
| Per-protocol set | 99 | 99 | 99 | 99 | 96 | 99 | 102 | 100 |
| Completed | 94 | 84 | 93 | 86 | 91 | 88 | 93 | 90 |
| Not completed | 6 | 17 | 6 | 16 | 8 | 12 | 11 | 12 |
| Withdrew: Withdrawal by subject | 3 | 9 | 1 | 6 | 4 | 4 | 2 | 5 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 3 | 6 | 3 | 9 | 3 | 6 | 8 | 5 |
| Withdrew: Death | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values reported greater than upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 41.4 nanograms (ng)/milliliter (mL) and ULOQ was 428000 ng/mL for manual assay; LLOQ was 47.6 ng/mL and 583000 ng/mL for automated assay for SR-1 IgG antibody. 95% confidence interval (CI) for GM value was calculated based on the t-distribution of the log-transformed values , then back transformed to the original scale for presentation.
| ng/mL | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo |
|---|---|---|---|---|---|---|---|---|
| Day 1 | 20.9 (20.5 to 21.2) | 23.2 (20.6 to 26.1) | 21.1 (20.5 to 21.7) | 22.8 (20.6 to 25.3) | 22.0 (20.8 to 23.2) | 21.2 (20.5 to 21.8) | 21.6 (20.7 to 22.6) | 21.6 (20.6 to 22.6) |
| Day 29 | 132.6 (103.5 to 169.9) | 210.3 (155.8 to 283.7) | 337.7 (262.1 to 435.1) | 341.2 (261.1 to 445.7) | 143.2 (110.8 to 185.1) | 173.1 (130.3 to 230.0) | 286.6 (226.8 to 362.1) | 23.2 (21.2 to 25.3) |
| Day 85 | 7677.6 (6050.4 to 9742.4) | 12511.1 (9778.6 to 16007.2) | 18298.5 (15411.6 to 21726.2) | 18793.1 (14816.9 to 23836.3) | 10351.3 (8109.8 to 13212.4) | 12207.4 (10039.2 to 14843.8) | 14372.3 (11741.2 to 17593.1) | 23.0 (20.0 to 26.4) |
| Day 197 | 18115.3 (15351.1 to 21377.2) | 21687.1 (17300.1 to 27186.5) | 33872.8 (28346.7 to 40476.1) | 38030.2 (31456.3 to 45977.9) | 21896.2 (17741.4 to 27023.9) | 27292.0 (22845.8 to 32603.5) | 27325.6 (22667.0 to 32941.7) | 24.1 (20.8 to 27.9) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 30 ng/mL and ULOQ was 214000 ng/mL for manual assay; LLOQ was 66.6 ng/mL and 215000 ng/mL for automated assay for SR-2 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
| ng/mL | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | Placebo |
|---|---|---|---|---|---|
| Day 1 | 16.5 (15.3 to 17.7) | 17.5 (15.4 to 19.8) | 17.1 (15.4 to 19.0) | 17.0 (15.3 to 18.9) | 18.0 (15.4 to 21.2) |
| Day 29 | 462.4 (361.2 to 591.9) | 517.0 (390.2 to 684.9) | 963.1 (750.9 to 1235.4) | 1051.5 (812.8 to 1360.2) | 17.5 (15.1 to 20.1) |
| Day 85 | 11868.7 (9422.5 to 14949.9) | 15853.4 (12610.0 to 19931.0) | 25840.4 (22010.1 to 30337.3) | 24519.3 (19478.4 to 30864.6) | 20.8 (15.2 to 28.4) |
| Day 197 | 19183.3 (16351.5 to 22505.6) | 21827.7 (17422.6 to 27346.6) | 36464.7 (31067.1 to 42800.0) | 38402.4 (32552.4 to 45303.7) | 21.5 (15.5 to 29.9) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 14.5 ng/mL and ULOQ was 299000 ng/mL for manual assay; LLOQ was 62.5 ng/mL and 296000 ng/mL for automated assay for SR-3 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
| ng/mL | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | Placebo |
|---|---|---|---|---|---|
| Day 1 | 10.0 (8.2 to 12.1) | 9.4 (7.9 to 11.2) | 8.6 (7.8 to 9.5) | 9.3 (8.0 to 10.8) | 10.4 (8.6 to 12.5) |
| Day 29 | 281.2 (220.1 to 359.4) | 265.1 (198.6 to 354.0) | 451.0 (351.9 to 577.9) | 499.7 (380.1 to 657.0) | 9.7 (8.1 to 11.5) |
| Day 85 | 18879.1 (14955.0 to 23833.0) | 24744.5 (19231.0 to 31838.6) | 39496.9 (33493.5 to 46576.4) | 38397.6 (30110.4 to 48965.7) | 12.2 (8.4 to 17.7) |
| Day 197 | 30597.1 (26195.4 to 35738.5) | 34358.4 (27397.3 to 43088.2) | 53775.7 (45890.0 to 63016.5) | 59961.2 (51353.0 to 70012.3) | 10.5 (7.9 to 13.9) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 32.6 ng/mL and ULOQ was 292000 ng/mL for manual assay; LLOQ was 59.7 ng/mL and 264000 ng/mL for automated assay for SR-4 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
| ng/mL | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | Placebo |
|---|---|---|---|---|---|
| Day 1 | 17.5 (16.4 to 18.8) | 18.4 (16.5 to 20.5) | 17.5 (16.4 to 18.8) | 18.9 (16.9 to 21.1) | 17.4 (16.1 to 18.9) |
| Day 29 | 278.3 (216.7 to 357.4) | 311.2 (233.9 to 414.0) | 461.7 (367.1 to 580.8) | 673.4 (512.3 to 885.1) | 16.8 (15.8 to 17.7) |
| Day 85 | 7657.5 (6041.3 to 9706.0) | 10956.1 (8618.8 to 13927.4) | 16893.9 (14300.6 to 19957.5) | 17014.8 (13540.2 to 21381.0) | 19.1 (14.7 to 24.8) |
| Day 197 | 16321.2 (13797.4 to 19306.7) | 18558.6 (14731.0 to 23380.8) | 30140.4 (25139.1 to 36136.6) | 33650.8 (28045.2 to 40376.9) | 21.0 (15.7 to 28.1) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 45.5 ng/mL and ULOQ was 298000 ng/mL for manual assay; LLOQ was 84.2 ng/mL and 319000 ng/mL for automated assay for SR-5 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
| ng/mL | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | Placebo |
|---|---|---|---|---|---|
| Day 1 | 23.1 (22.6 to 23.7) | 24.8 (22.5 to 27.4) | 23.2 (22.6 to 23.7) | 24.1 (22.2 to 26.2) | 23.5 (22.4 to 24.7) |
| Day 29 | 227.8 (181.1 to 286.7) | 312.8 (237.5 to 411.9) | 429.2 (342.0 to 538.7) | 574.3 (447.4 to 737.3) | 23.5 (22.4 to 24.6) |
| Day 85 | 12397.8 (9776.0 to 15722.8) | 18278.8 (14417.0 to 23175.1) | 28935.8 (24549.3 to 34106.2) | 29379.4 (23500.4 to 36729.0) | 26.5 (20.2 to 34.9) |
| Day 197 | 25936.7 (22160.8 to 30355.9) | 30441.9 (24264.0 to 38192.7) | 48316.4 (40666.4 to 57405.4) | 55926.3 (47330.2 to 66083.6) | 28.8 (21.3 to 38.8) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 18.1 ng/mL and ULOQ was 203000 ng/mL for manual assay; LLOQ was 68.7 ng/mL and 248000 ng/mL for automated assay for SR-6 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
| ng/mL | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | Placebo |
|---|---|---|---|---|---|
| Day 1 | 15.7 (12.9 to 19.0) | 17.8 (14.2 to 22.5) | 17.4 (14.0 to 21.7) | 16.5 (13.3 to 20.6) | 16.1 (12.4 to 20.8) |
| Day 29 | 908.6 (686.7 to 1202.2) | 966.1 (707.5 to 1319.2) | 1455.3 (1098.3 to 1928.3) | 2053.0 (1519.8 to 2773.3) | 17.4 (12.8 to 23.7) |
| Day 85 | 10562.2 (8398.7 to 13283.0) | 15196.8 (12110.6 to 19069.5) | 24822.5 (20955.4 to 29403.1) | 24350.5 (19698.1 to 30101.7) | 19.1 (13.2 to 27.6) |
| Day 197 | 21974.2 (18498.7 to 26102.8) | 24469.9 (19561.2 to 30610.5) | 40282.3 (33744.1 to 48087.4) | 45703.0 (38542.2 to 54194.3) | 20.5 (13.8 to 30.5) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 13 ng/mL and ULOQ was 197000 ng/mL for manual assay; LLOQ was 78.9 ng/mL and 174000 ng/mL for automated assay for SR-7 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
| ng/mL | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | Placebo |
|---|---|---|---|---|---|
| Day 1 | 9.5 (7.8 to 11.4) | 9.4 (7.8 to 11.3) | 8.9 (7.7 to 10.3) | 9.3 (7.8 to 11.0) | 9.9 (8.0 to 12.3) |
| Day 29 | 360.8 (281.2 to 462.8) | 314.7 (226.3 to 437.6) | 567.4 (444.9 to 723.7) | 730.4 (533.6 to 999.7) | 9.3 (7.6 to 11.3) |
| Day 85 | 15651.7 (12231.7 to 20028.0) | 18865.4 (14538.3 to 24480.3) | 32934.0 (27492.3 to 39452.9) | 28756.5 (22583.1 to 36617.5) | 11.4 (7.8 to 16.6) |
| Day 197 | 27210.2 (23148.9 to 31984.0) | 26425.1 (21070.6 to 33140.4) | 44179.6 (37498.2 to 52051.3) | 47777.3 (40846.7 to 55883.8) | 11.0 (7.9 to 15.4) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 41.4 ng/mL and ULOQ was 428000 ng/mL for manual assay; LLOQ was 47.6 ng/mL and 583000 ng/mL for automated assay for SR-1 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation.
| ratio | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo |
|---|---|---|---|---|---|---|---|---|
| Day 29 | 6.36 (4.96 to 8.15) | 9.07 (6.97 to 11.81) | 16.00 (12.45 to 20.56) | 15.13 (11.87 to 19.28) | 6.52 (5.09 to 8.35) | 8.18 (6.18 to 10.83) | 13.24 (10.45 to 16.77) | 1.07 (0.99 to 1.16) |
| Day 85 | 367.86 (289.59 to 467.29) | 543.18 (424.67 to 694.76) | 866.31 (728.39 to 1030.33) | 822.95 (651.97 to 1038.75) | 470.15 (366.95 to 602.37) | 581.89 (480.79 to 704.25) | 662.04 (540.01 to 811.66) | 1.06 (0.93 to 1.22) |
| Day 197 | 867.49 (733.47 to 1026.00) | 938.35 (744.25 to 1183.07) | 1601.46 (1338.41 to 1916.20) | 1658.31 (1352.59 to 2033.15) | 993.15 (794.82 to 1240.96) | 1300.55 (1088.80 to 1553.50) | 1253.29 (1036.49 to 1515.44) | 1.11 (0.96 to 1.26) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 30 ng/mL and ULOQ was 214000 ng/mL for manual assay; LLOQ was 66.6 ng/mL and 215000 ng/mL for automated assay for SR-2 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
| ratio | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | Placebo |
|---|---|---|---|---|---|
| Day 29 | 28.03 (22.24 to 35.34) | 29.49 (22.81 to 38.12) | 56.25 (44.00 to 71.91) | 61.84 (47.73 to 80.11) | 0.97 (0.93 to 1.01) |
| Day 85 | 718.13 (566.61 to 910.17) | 902.85 (704.35 to 1157.29) | 1500.72 (1221.09 to 1844.39) | 1438.92 (1128.33 to 1835.01) | 1.15 (0.86 to 1.53) |
| Day 197 | 1165.32 (984.17 to 1379.80) | 1236.85 (958.68 to 1595.74) | 2188.32 (1824.82 to 2624.23) | 2316.91 (1920.38 to 2795.31) | 1.19 (0.89 to 1.59) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 14.5 ng/mL and ULOQ was 299000 ng/mL for manual assay; LLOQ was 62.5 ng/mL and 296000 ng/mL for automated assay for SR-3 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
| ratio | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | Placebo |
|---|---|---|---|---|---|
| Day 29 | 27.98 (21.92 to 35.70) | 28.19 (21.73 to 36.57) | 52.58 (40.16 to 68.84) | 53.48 (40.99 to 69.76) | 0.93 (0.86 to 1.01) |
| Day 85 | 1871.56 (1397.22 to 2506.93) | 2677.78 (2008.72 to 3569.68) | 4651.11 (3749.37 to 5769.72) | 4106.89 (3104.97 to 5432.10) | 1.18 (0.83 to 1.68) |
| Day 197 | 3249.93 (2735.98 to 3860.42) | 3689.50 (2820.14 to 4826.86) | 6328.99 (5160.22 to 7762.48) | 6487.62 (5164.85 to 8149.16) | 1.02 (0.77 to 1.36) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 32.6 ng/mL and ULOQ was 292000 ng/mL for manual assay; LLOQ was 59.7 ng/mL and 264000 ng/mL for automated assay for SR-4 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
| ratio | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | Placebo |
|---|---|---|---|---|---|
| Day 29 | 15.84 (12.51 to 20.05) | 16.90 (13.17 to 21.67) | 26.32 (20.83 to 33.25) | 36.26 (27.78 to 47.32) | 0.96 (0.91 to 1.01) |
| Day 85 | 435.52 (341.99 to 554.63) | 600.04 (470.06 to 765.97) | 960.06 (795.84 to 1158.16) | 901.26 (709.46 to 1144.93) | 1.09 (0.84 to 1.42) |
| Day 197 | 923.60 (773.02 to 1103.50) | 1012.74 (796.67 to 1287.41) | 1704.02 (1391.81 to 2086.25) | 1784.54 (1452.04 to 2193.18) | 1.20 (0.90 to 1.61) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 45.5 ng/mL and ULOQ was 298000 ng/mL for manual assay; LLOQ was 84.2 ng/mL and 319000 ng/mL for automated assay for SR-5 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
| ratio | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | Placebo |
|---|---|---|---|---|---|
| Day 29 | 9.84 (7.86 to 12.32) | 12.58 (9.76 to 16.22) | 18.53 (14.72 to 23.33) | 23.79 (18.92 to 29.91) | 1.00 (0.96 to 1.05) |
| Day 85 | 535.26 (422.24 to 678.54) | 734.72 (574.47 to 939.67) | 1248.40 (1051.92 to 1481.58) | 1221.90 (977.12 to 1528.01) | 1.13 (0.86 to 1.48) |
| Day 197 | 1118.45 (957.19 to 1306.88) | 1220.14 (964.85 to 1542.97) | 2081.93 (1742.35 to 2487.70) | 2313.13 (1937.15 to 2762.07) | 1.22 (0.90 to 1.65) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 18.1 ng/mL and ULOQ was 203000 ng/mL for manual assay; LLOQ was 68.7 ng/mL and 248000 ng/mL for automated assay for SR-6 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
| ratio | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | Placebo |
|---|---|---|---|---|---|
| Day 29 | 57.36 (44.30 to 74.28) | 54.45 (40.29 to 73.59) | 83.55 (61.40 to 113.68) | 126.77 (92.88 to 173.02) | 1.08 (0.88 to 1.34) |
| Day 85 | 687.70 (530.80 to 890.99) | 858.93 (628.91 to 1173.07) | 1448.42 (1066.27 to 1967.54) | 1459.96 (1098.19 to 1940.90) | 1.20 (0.97 to 1.47) |
| Day 197 | 1422.17 (1110.28 to 1821.67) | 1353.77 (980.02 to 1870.04) | 2444.57 (1849.48 to 3231.14) | 2811.21 (2119.73 to 3728.26) | 1.29 (0.94 to 1.76) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 13 ng/mL and ULOQ was 197000 ng/mL for manual assay; LLOQ was 78.9 ng/mL and 174000 ng/mL for automated assay for SR-7 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.
| ratio | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | Placebo |
|---|---|---|---|---|---|
| Day 29 | 37.83 (29.46 to 48.57) | 33.46 (24.91 to 44.95) | 63.76 (48.29 to 84.18) | 79.96 (58.39 to 109.51) | 0.93 (0.88 to 1.00) |
| Day 85 | 1634.53 (1211.14 to 2205.93) | 2059.80 (1545.71 to 2744.87) | 3764.69 (2894.54 to 4896.43) | 3085.38 (2305.20 to 4129.62) | 1.17 (0.82 to 1.65) |
| Day 197 | 2989.02 (2414.14 to 3700.80) | 2882.41 (2191.50 to 3791.14) | 5113.85 (4044.21 to 6466.39) | 5235.80 (4102.95 to 6681.44) | 1.13 (0.84 to 1.51) |
Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection | 70 | 80 | 82 | 91 | 64 | 77 | 86 | 33 |
Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 57 Injection | 79 | 80 | 90 | 96 | 70 | 82 | 88 | 33 |
Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 169 Injection | 81 | 87 | 81 | 92 | 76 | 82 | 88 | 26 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Unsolicited AEs | 38 | 38 | 42 | 47 | 29 | 38 | 36 | 37 |
A MAAE is an AE that led to an unscheduled visit to a healthcare practitioner. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor were required. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo |
|---|---|---|---|---|---|---|---|---|
| MAAEs | 39 | 38 | 36 | 42 | 42 | 40 | 46 | 39 |
| AESIs | 0 | 1 | 4 | 0 | 1 | 2 | 2 | 2 |
| SAEs | 4 | 4 | 6 | 4 | 6 | 3 | 4 | 7 |
| AEs Leading to Study Discontinuation | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 |
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.
| Participants | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo |
|---|---|---|---|---|---|---|---|---|
| Deaths | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 |
| Deaths related to study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over All-cause mortality, SAEs, AESIs, MAAEs, and AEs leading to study discontinuation were collected from Day 1 up to Month 18. Other (non-serious) adverse events were collected from the time of injection through 28 days after each injection, unless they met the criteria for SAEs, AESIs, MAAEs, or AEs led to study discontinuation.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| mRNA-1975 Dose Level 1 | 0/100 (0%) | 4/100 (4%) | 12/100 (12%) |
| mRNA-1975 Dose Level 2 | 1/101 (1%) | 4/101 (4%) | 16/101 (15.8%) |
| mRNA-1975 Dose Level 3 | 0/99 (0%) | 6/99 (6.1%) | 6/99 (6.1%) |
| mRNA-1975 Dose Level 4 | 1/102 (1%) | 4/102 (3.9%) | 13/102 (12.7%) |
| mRNA-1982 Dose Level 1 | 0/99 (0%) | 6/98 (6.1%) | 15/98 (15.3%) |
| mRNA-1982 Dose Level 2 | 1/100 (1%) | 3/100 (3%) | 14/100 (14%) |
| mRNA-1982 Dose Level 3 | 0/104 (0%) | 4/105 (3.8%) | 9/105 (8.6%) |
| Placebo | 1/102 (1%) | 7/101 (6.9%) | 12/101 (11.9%) |
| Event | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo |
|---|---|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/100 | 0/101 | 2/99 | 0/102 | 0/98 | 0/100 | 0/105 | 0/101 |
| AppendicitisInfections and infestations | 0/100 | 0/101 | 0/99 | 0/102 | 1/98 | 0/100 | 0/105 | 0/101 |
| COVID-19Infections and infestations | 0/100 | 0/101 | 0/99 | 0/102 | 1/98 | 0/100 | 0/105 | 0/101 |
| Rhinovirus infectionInfections and infestations | 0/100 | 0/101 | 0/99 | 0/102 | 1/98 | 0/100 | 0/105 | 0/101 |
| Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/100 | 0/101 | 0/99 | 0/102 | 1/98 | 0/100 | 0/105 | 0/101 |
| Cardiac failure acuteCardiac disorders | 0/100 | 0/101 | 0/99 | 0/102 | 1/98 | 0/100 | 0/105 | 0/101 |
| Subclavian steal syndromeVascular disorders | 0/100 | 0/101 | 0/99 | 0/102 | 1/98 | 0/100 | 0/105 | 0/101 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/100 | 0/101 | 0/99 | 0/102 | 1/98 | 0/100 | 0/105 | 0/101 |
| Renal impairmentRenal and urinary disorders | 0/100 | 0/101 | 0/99 | 0/102 | 1/98 | 0/100 | 0/105 | 0/101 |
| PyelonephritisInfections and infestations | 0/100 | 0/101 | 1/99 | 0/102 | 0/98 | 0/100 | 0/105 | 0/101 |
| Event | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo |
|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 7/100 | 8/101 | 3/99 | 6/102 | 8/98 | 8/100 | 6/105 | 5/101 |
| COVID-19Infections and infestations | 5/100 | 8/101 | 2/99 | 7/102 | 6/98 | 5/100 | 2/105 | 6/101 |
| RashSkin and subcutaneous tissue disorders | 1/100 | 2/101 | 1/99 | 1/102 | 5/98 | 3/100 | 1/105 | 1/101 |
The Full Analysis Set included all randomly assigned participants who received the study injection.
| Age, Continuous(years) | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 48.5 ± 13.72 | 50.5 ± 13.76 | 50.4 ± 14.66 | 49.6 ± 12.81 | 51.1 ± 13.95 | 49.8 ± 15.05 | 48.9 ± 14.77 | 51.2 ± 12.93 | 50.0 ± 13.95 |
| Sex: Female, Male(Participants) | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 42 | 53 | 57 | 56 | 53 | 50 | 54 | 58 | 423 |
| Male | 58 | 48 | 42 | 46 | 46 | 50 | 50 | 43 | 383 |
| Ethnicity (NIH/OMB)(Participants) | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 11 | 4 | 6 | 6 | 9 | 13 | 8 | 63 |
| Not Hispanic or Latino | 91 | 86 | 91 | 95 | 90 | 90 | 90 | 93 | 726 |
| Unknown or Not Reported | 3 | 4 | 4 | 1 | 3 | 1 | 1 | 0 | 17 |
| Race/Ethnicity, Customized(Participants) | mRNA-1975 Dose Level 1 | mRNA-1975 Dose Level 2 | mRNA-1975 Dose Level 3 | mRNA-1975 Dose Level 4 | mRNA-1982 Dose Level 1 | mRNA-1982 Dose Level 2 | mRNA-1982 Dose Level 3 | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| White | 78 | 74 | 76 | 84 | 77 | 79 | 73 | 79 | 620 |
| Black | 15 | 21 | 20 | 13 | 17 | 13 | 22 | 18 | 139 |
| Asian | 5 | 3 | 1 | 3 | 2 | 1 | 5 | 4 | 24 |
| American Indian or Alaska Native | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Other | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Multiple | 1 | 1 | 1 | 1 | 1 | 5 | 1 | 0 | 11 |
| Not reported | 1 | 0 | 1 | 0 | 2 | 1 | 2 | 0 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2023 to primary completion in May 2025, 22 months.
Results were first posted in Jul 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.